Molyneux David H
Lymphatic Filariasis Support Centre, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK.
Adv Parasitol. 2006;61:1-45. doi: 10.1016/S0065-308X(05)61001-9.
The control of parasitic diseases of humans has been undertaken since the aetiology and natural history of the infections was recognized and the deleterious effects on human health and well-being appreciated by policy makers, medical practitioners and public health specialists. However, while some parasitic infections such as malaria have proved difficult to control, as defined by a sustained reduction in incidence, others, particularly helminth infections can be effectively controlled. The different approaches to control from diagnosis, to treatment and cure of the clinically sick patient, to control the transmission within the community by preventative chemotherapy and vector control are outlined. The concepts of eradication, elimination and control are defined and examples of success summarized. Overviews of the health policy and financing environment in which programmes to control or eliminate parasitic diseases are positioned and the development of public-private partnerships as vehicles for product development or access to drugs for parasite disease control are discussed. Failure to sustain control of parasites may be due to development of drug resistance or the failure to implement proven strategies as a result of decreased resources within the health system, decentralization of health management through health-sector reform and the lack of financial and human resources in settings where per capita government expenditure on health may be less than $US 5 per year. However, success has been achieved in several large-scale programmes through sustained national government investment and/or committed donor support. It is also widely accepted that the level of investment in drug development for the parasitic diseases of poor populations is an unattractive option for pharmaceutical companies. The development of partnerships to specifically address this need provides some hope that the intractable problems of the treatment regimens for the trypanosomiases and leishmaniases can be solved in the not too distant future. However, it will be difficult to implement and sustain such interventions in fragile health services often in settings where resources are limited but also in unstable, conflict-affected or post-conflict countries. Emphasis is placed on the importance of co-endemicity and polyparasitism and the opportunity to control parasites susceptible to cost-effective and proven chemotherapeutic interventions for a package of diseases which can be implemented at low cost and which would benefit the poorest and most marginalized groups. The ecology of parasitic diseases is discussed in the context of changing ecology, environment, sociopolitical developments and climate change. These drivers of global change will affect the epidemiology of parasites over the coming decades, while in many of the most endemic and impoverished countries parasitic infections will be accorded lower priority as resourced stressed health systems cope with the burden of the higher-profile killing diseases viz., HIV/AIDS, TB and malaria. There is a need for more holistic thinking about the interactions between parasites and other infections. It is clear that as the prevalence and awareness of HIV has increased, there is a growing recognition of a host of complex interactions that determine disease outcome in individual patients. The competition for resources in the health as well as other social sectors will be a continuing challenge; effective parasite control will be dependent on how such resources are accessed and deployed to effectively address well-defined problems some of which are readily amenable to successful interventions with proven methods. In the health sector, the problems of the HIV/AIDS and TB pandemics and the problem of the emerging burden of chronic non-communicable diseases will be significant competitors for these limited resources as parasitic infections aside from malaria tend to be chronic disabling problems of the poorest who have limited access to scarce health services and are representative of the poorest quintile. Prioritization and advocacy for parasite control in the national and international political environments is the challenge.
自从感染的病因和自然史被认识,且政策制定者、医学从业者和公共卫生专家认识到其对人类健康和福祉的有害影响以来,人们就一直在努力控制人类的寄生虫病。然而,虽然一些寄生虫感染,如疟疾,已证明难以按照发病率持续下降的定义进行控制,但其他感染,特别是蠕虫感染,可以得到有效控制。本文概述了从诊断到治疗和治愈临床患者,再到通过预防性化疗和病媒控制在社区内控制传播的不同控制方法。定义了根除、消除和控制的概念,并总结了成功案例。讨论了控制或消除寄生虫病项目所处的卫生政策和筹资环境,以及公私伙伴关系作为产品开发或获取寄生虫病控制药物手段的发展情况。未能持续控制寄生虫可能是由于耐药性的产生,或者由于卫生系统资源减少、通过卫生部门改革实现卫生管理权力下放以及人均政府卫生支出可能每年低于5美元的地区缺乏财政和人力资源,导致未能实施已证实的战略。然而,通过国家政府的持续投资和/或捐助方的坚定支持,一些大规模项目已经取得了成功。人们还普遍认为,对贫困人口寄生虫病药物研发的投资水平对制药公司来说缺乏吸引力。建立专门满足这一需求的伙伴关系,为在不久的将来解决锥虫病和利什曼病治疗方案的棘手问题带来了一些希望。然而,在资源往往有限的脆弱卫生服务中,以及在不稳定、受冲突影响或冲突后国家,实施和维持此类干预措施将很困难。重点强调了共流行和多重寄生虫感染的重要性,以及控制对具有成本效益且已证实的化疗干预措施敏感的寄生虫的机会,这些干预措施可针对一系列疾病实施,成本低廉,将使最贫穷和最边缘化群体受益。本文在生态变化、环境、社会政治发展和气候变化的背景下讨论了寄生虫病的生态学。这些全球变化驱动因素将在未来几十年影响寄生虫的流行病学,而在许多寄生虫病流行最严重和最贫困的国家,由于资源紧张的卫生系统要应对诸如艾滋病毒/艾滋病、结核病和疟疾等高致死率疾病的负担,寄生虫感染将被置于较低优先级。需要对寄生虫与其他感染之间的相互作用进行更全面的思考。显然,随着艾滋病毒流行率和认知度的提高,人们越来越认识到一系列复杂的相互作用决定了个体患者的疾病结局。卫生部门以及其他社会部门对资源的竞争将是一个持续的挑战;有效的寄生虫控制将取决于如何获取和调配这些资源,以有效解决一些明确的问题,其中一些问题很容易通过已证实的方法成功干预。在卫生部门,艾滋病毒/艾滋病和结核病大流行问题以及新出现的慢性非传染性疾病负担问题将成为这些有限资源争夺的重要对手,因为除疟疾外的寄生虫感染往往是最贫困人群的慢性致残问题,他们获得稀缺卫生服务的机会有限,且代表了最贫困的五分之一人口。在国家和国际政治环境中对寄生虫控制进行优先排序和宣传是一项挑战。